Taken together, the demonstrated effects of NLRP3 attenuation in both T2D and non T2D rodent and human models suggest a glucose independent mechanism likely to contribute to the benefits seen in HF and MACE in human studies with SGLT2 inhibition. Here, NLRP3 is linked to type 2 diabetes mellitus.